View Author
Nierop, C.A.
( C.A. Nierop)
diarrhea patient -11 cpt -11 neomycin glucuronidase activity course cancer -38 glucuronidase plasma activity sn -38 pharmacokinetic study treatment irinotecan sn -38g delayed-type diarrhea administration cpt -11-induced diarrhea delayed-type value -11-induced level metabolite effect grade disposition concentration range university hospital rotterdam cpt -11 administration rotterdam toxicity plasma pharmacokinetics sample cotreatment presence auc 0 model agent verweij antibiotic hematological toxicity cpt -11 metabolism drug administration aminoglycoside antibiotic neomycin limit jonge cpt -11 diarrhea sparreboom infusion cpt -11 treatment evaluable microorganism coadministration microflora terminal disposition phase plasma concentration-time curve extent topoisomerase i inhibitors glucuronidation cpt -11 infusion rotterdam cancer institute difference treatment course biliary absence grade 2 diarrhea bruijn aucsn analysis phase serum inhibitor isoform decrease 1998. ethyl
1 Most Recent Publications
|
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients
(Article)
Kehrer, D.F.S. Sparreboom, A. Verweij, J. Bruijn, P. de Nierop, C.A. Schraaf, J. van de Ruijgrok, E.J. Jonge, M.J.A. de |
2001-01-01
|